Understanding the GLP-1 Drug Supply Crisis in the United States: A Comprehensive OverviewThe pharmaceutical landscape in the United States is presently experiencing a transformative shift, driven mostly by the extraordinary need for Glucagon-like peptide-1 (GLP-1) receptor agonists. Originally established to treat Type 2 diabetes, these medications-- consisting of brand names